IVIG is recommended as first-line therapy in CIDP. Immunosuppressive therapy in combination with IVIG can be considered in refractory cases.
All patients receiving IVIG for chronic treatment of CIDP should be followed by a neuromuscular specialist.
Initial dose: 2 g/kg divided over 2 to 5 days.
Maintenance dose: 1 g/kg every 3 weeks.
Continued use should be based on objective measures of sustained effectiveness.
Aim for minimum dose to maintain optimal functional status.